A record of what Nuvama Analysis said publicly, with the source. Not advice.
Pending — not yet graded
“Nuvama expects Dr. Reddy's revenue and EBITDA to grow by 17% and 13% YoY respectively, with EBITDA margins at 27.5% for Q3FY25, aided by strong gRevlimid contribution driving US revenue to $427 million. Indian business is projected to grow 19% YoY, supported by organic growth and vaccine contributions, alongside anticipated growth in China, Brazil, and Russia.”
Nuvama Analysis’s track record (trackable calls only): 161 graded calls · 95% CI 35–50%
Dr. Reddy'sBullishCalled 22 Jan 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Nuvama Analysis’s full track record